Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells

Cancer Letters

Volumn 366, Issue 1, 2015, Pages 32-43

  Steinwascher, Sofie ^a   Nugues, Anne Lucie ^a   Schoeneberger, Hannah ^a   Fulda, Simone ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; Leukemia; Necroptosis; Smac

Indexed keywords

BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; BV6 PEPTIDE; CASPASE; HISTONE DEACETYLASE INHIBITOR; OLIGOPEPTIDE; PEPTIDE CHLOROMETHYL KETONE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; DRUG EFFECTS; DRUG POTENTIATION; HUMAN; LEUKEMIA, MYELOID, ACUTE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AMINO ACID CHLOROMETHYL KETONES; APOPTOSIS; CASPASES; CELL LINE, TUMOR; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; OLIGOPEPTIDES; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84937519269     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.05.020     Document Type: Article

References (44)

1. Estey E., Dohner H. Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
2. Fulda S., Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
3. Galluzzi L., Vitale I., Abrams J.M., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012, 19:107-120.
4. Taylor R.C., Cullen S.P., Martin S.J. Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol 2008, 9:231-241.
5. Vandenabeele P., Galluzzi L., Vanden Berghe T., Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat. Rev. Mol. Cell Biol 2010, 11:700-714.
6. Oberst A., Dillon C.P., Weinlich R., McCormick L.L., Fitzgerald P., Pop C., et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 2011, 471:363-367.
7. Fulda S., Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov 2012, 11:109-124.
8. Tamm I., Kornblau S.M., Segall H., Krajewski S., Welsh K., Kitada S., et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res 2000, 6:1796-1803.
9. Tamm I., Richter S., Scholz F., Schmelz K., Oltersdorf D., Karawajew L., et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol. J. 2004, 5:489-495.
10. Bullinger L., Rucker F.G., Kurz S., Du J., Scholl C., Sander S., et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 2007, 110:1291-1300.
11. Luck S.C., Russ A.C., Botzenhardt U., Paschka P., Schlenk R.F., Dohner H., et al. Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups. Leukemia 2011, 25:1728-1738.
12. Hess C.J., Berkhof J., Denkers F., Ossenkoppele G.J., Schouten J.P., Oudejans J.J., et al. Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia. J. Clin. Oncol 2007, 25:1209-1215.
13. Varfolomeev E., Blankenship J.W., Wayson S.M., Fedorova A.V., Kayagaki N., Garg P., et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007, 131:669-681.
14. Vince J.E., Wong W.W., Khan N., Feltham R., Chau D., Ahmed A.U., et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007, 131:682-693.
15. Wang L., Du F., Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008, 133:693-703.
16. Chromik J., Safferthal C., Serve H., Fulda S. Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis. Cancer Lett 2014, 344:101-109.
17. Steinhart L., Belz K., Fulda S. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis 2013, 4:e802.
18. Garcia-Manero G. Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy. Best Pract. Res. Clin. Haematol 2012, 25:427-435.
19. Fulda S., Strauss G., Meyer E., Debatin K.M. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. Blood 2000, 95:301-308.
20. Fakler M., Loeder S., Vogler M., Schneider K., Jeremias I., Debatin K.M., et al. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009, 113:1710-1722.
21. Belz K., Schoeneberger H., Wehner S., Weigert A., Bonig H., Klingebiel T., et al. Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly. Blood 2014, 124:240-250.
22. Schenk B., Fulda S. Reactive oxygen species regulate Smac mimetic/TNFalpha-induced necroptotic signaling and cell death. Oncogene 2015, Apr 13 [E-pub ahead of print.
23. Chou T.C. The median-effect principle and the combination index for quantitation of synergism and antagonism. Synergism and Antagonism in Chemotherapy 1991, 61-102. Academic Press, San Diego, CA. T.C. Chou (Ed.).
24. Bertrand M.J., Milutinovic S., Dickson K.M., Ho W.C., Boudreault A., Durkin J., et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 2008, 30:689-700.
25. Petersen S.L., Wang L., Yalcin-Chin A., Li L., Peyton M., Minna J., et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007, 12:445-456.
26. Sun L., Wang H., Wang Z., He S., Chen S., Liao D., et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012, 148:213-227.
27. Fulda S. Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies. Leukemia 2012, 26:1155-1165.
28. Carter B.Z., Mak P.Y., Mak D.H., Shi Y., Qiu Y., Bogenberger J.M., et al. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J. Natl Cancer Inst 2014, 106:djt440.
29. Weisberg E., Kung A.L., Wright R.D., Moreno D., Catley L., Ray A., et al. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol. Cancer Ther 2007, 6:1951-1961.
30. Weisberg E., Ray A., Barrett R., Nelson E., Christie A.L., Porter D., et al. Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia 2010, 24:2100-2109.
31. Carter B.Z., Gronda M., Wang Z., Welsh K., Pinilla C., Andreeff M., et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood 2005, 105:4043-4050.
32. Servida F., Lecis D., Scavullo C., Drago C., Seneci P., Carlo-Stella C., et al. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis. Invest. New Drugs 2011, 29:1264-1275.
33. Wagner L., Marschall V., Karl S., Cristofanon S., Zobel K., Deshayes K., et al. Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-kappaB-dependent manner. Oncogene 2013, 32:988-997.
34. Vogler M., Walczak H., Stadel D., Haas T.L., Genze F., Jovanovic M., et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009, 69:2425-2434.
35. Abhari B.A., Cristofanon S., Kappler R., von Schweinitz D., Humphreys R., Fulda S. RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex. Oncogene 2013, 32:3263-3273.
36. Berger R., Jennewein C., Marschall V., Karl S., Cristofanon S., Wagner L., et al. NF-{kappa}B is required for smac mimetic-mediated sensitization of glioblastoma cells for {gamma}-irradiation-induced apoptosis. Mol. Cancer Ther 2011, 10:1867-1875.
37. Loeder S., Fakler M., Schoeneberger H., Cristofanon S., Leibacher J., Vanlangenakker N., et al. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia 2012, 26:1020-1029.
38. Cristofanon S., Abhari B.A., Krueger M., Tchoghandjian A., Momma S., Calaminus C., et al. Identification of RIP1 as a critical mediator of Smac mimetic-mediated sensitization of glioblastoma cells for Drozitumab-induced apoptosis. Cell Death Dis 2015, 6:e1724.
39. Basit F., Humphreys R., Fulda S. RIP1 protein-dependent assembly of a cytosolic cell death complex is required for inhibitor of apoptosis (IAP) inhibitor-mediated sensitization to lexatumumab-induced apoptosis. J. Biol. Chem 2012, 287:38767-38777.
40. Schoeneberger H., Belz K., Schenk B., Fulda S. Impairment of antioxidant defense via glutathione depletion sensitizes acute lymphoblastic leukemia cells for Smac mimetic-induced cell death. Oncogene 2014, Nov 10 [E-pub ahead of print.
41. Vellanki S.H., Grabrucker A., Liebau S., Proepper C., Eramo A., Braun V., et al. Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia 2009, 11:743-752.
42. Bangert A., Cristofanon S., Eckhardt I., Abhari B.A., Kolodziej S., Hacker S., et al. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene 2012, 31:4677-4688.
43. Hacker S., Dittrich A., Mohr A., Schweitzer T., Rutkowski S., Krauss J., et al. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 2009, 28:3097-3110.
44. Hacker S., Karl S., Mader I., Cristofanon S., Schweitzer T., Krauss J., et al. Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation. Oncogene 2011, 30:2275-2281.